Unicycive Therapeutics

Unicycive is a biotechnology company developing new therapies for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binder currently in development for the treatment of hyperphosphatemia. UNI-494 is a patented new chemical entity being developed for the treatment of acute kidney injury and is currently in the late preclinical development stage.